Treatment limitations or discontinuation in patients with benign pulmonary diseases

Anita Rath Sørensen; Elisabeth Bendstrup; Anders Løkke; Ingrid Louise Titlestad; Jens Ulrik Jensen; Laura Thomsen; Nassim Roberts; Pia Gjørup; Saher Shaker; Svend Gundestrup; Torgny Wilcke; Ulla Møller Weinreich; Kristoffer Marsaa

Treatment limitations or discontinuation in patients with benign pulmonary diseases

Anita Rath Sørensen, Elisabeth Bendstrup, Anders Løkke, Ingrid Louise Titlestad, Jens Ulrik Jensen, Laura Thomsen, Nassim Roberts, Pia Gjørup, Saher Shaker, Svend Gundestrup, Torgny Wilcke, Ulla Møller Weinreich, Kristoffer Marsaa

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

Abstract

The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.

Original language	English
Journal	Ugeskrift for Læger
Volume	180
Issue	39
ISSN	0041-5782
Publication status	Published - 24 Sept 2018

Cite this

@article{b141323a0ef04113bd9a9c65b9e519f1,

title = "Treatment limitations or discontinuation in patients with benign pulmonary diseases",

abstract = "The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.",

author = "S{\o}rensen, {Anita Rath} and Elisabeth Bendstrup and Anders L{\o}kke and Titlestad, {Ingrid Louise} and Jensen, {Jens Ulrik} and Laura Thomsen and Nassim Roberts and Pia Gj{\o}rup and Saher Shaker and Svend Gundestrup and Torgny Wilcke and Weinreich, {Ulla M{\o}ller} and Kristoffer Marsaa",

year = "2018",

month = sep,

day = "24",

language = "English",

volume = "180",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "39",

}

TY - JOUR

T1 - Treatment limitations or discontinuation in patients with benign pulmonary diseases

AU - Sørensen, Anita Rath

AU - Bendstrup, Elisabeth

AU - Løkke, Anders

AU - Titlestad, Ingrid Louise

AU - Jensen, Jens Ulrik

AU - Thomsen, Laura

AU - Roberts, Nassim

AU - Gjørup, Pia

AU - Shaker, Saher

AU - Gundestrup, Svend

AU - Wilcke, Torgny

AU - Weinreich, Ulla Møller

AU - Marsaa, Kristoffer

PY - 2018/9/24

Y1 - 2018/9/24

N2 - The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.

AB - The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.

UR - http://www.scopus.com/inward/record.url?scp=85054090930&partnerID=8YFLogxK

M3 - Review

C2 - 30274574

AN - SCOPUS:85054090930

SN - 0041-5782

VL - 180

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 39

ER -

Treatment limitations or discontinuation in patients with benign pulmonary diseases

Abstract

Other files and links

Fingerprint

Cite this